Drugs / CDCA1
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01069575 | Feb 2010 → Mar 2019 | non-small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1 | NCT01069653 | Feb 2010 → Mar 2019 | small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1 | NCT01259505 | Dec 2009 → Jun 2012 | breast cancer | Tokyo Medical University | Completed | No outcome recorded |
| Phase 1 | NCT00874588 | Mar 2009 → Jun 2012 | non-small cell lung carcinoma | Fukushima Medical University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01950156 | Sep 2011 → Mar 2019 | non-small cell lung carcinoma | Shiga University | Completed | No outcome recorded |
| Phase 1/2 | NCT01225471 | Jun 2009 → May 2011 | prostate cancer | Iwate Medical University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01267578 | Apr 2010 → May 2011 | esophageal cancer | University of Yamanashi | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDCA1 | “Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides” NCT01267578 ↗ |
| Modality | Peptide | “CDCA1 peptide” NCT01069575 ↗ |
| Route | Subcutaneous | “the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection” NCT01069653 ↗ |
| Target | CDCA1 | “URLC10, CDCA1, and KIF20A, as targets for vaccination against lung cancer” NCT01950156 ↗ |